Twitter Beğeni Hilesi

ESMO 24: Bayer Prostate Drugs Old And New Deliver On Survival. The German group's goal of expanding Nubeqa into wider prostate cancer patient populations has probably been reached with the results...      Related StoriesESMO 24: Bayer... ow.ly/2sut105J57x #PharmaScrip

Kisqali Label Expansion Will Double Market Size Opportunity. The US FDA approved the drug with a broad label for patients with HR+/HER2- early breast cancer at high risk...      Related StoriesOrganon Moves Into Branded Dermatology With... ow.ly/ml4G105J85X #PharmaScrip

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates. Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.... ow.ly/Gqto105JajZ #PharmaScrip

Taisho Makes Japan Vornorexant Filing, Hopes To Dent Insomnia Market. Taisho’s in-house insomnia therapeutic candidate vornorexant offers a potential advantage of a shorter half-life compared to its competitors, which can...      Related... ow.ly/4ngZ105JbnC #PharmaScrip

Newron Weighs Up Partners Or M&A As Excitement Grows Over Antipsychotic. The Italian firm has received "several indications of interest" in evenamide, which is being prepped to go into Phase III...      Related StoriesExecutives On The... ow.ly/9ORH105JcBe #PharmaScrip

Executives On The Move: Four New CEOs And Four New CFOs Among This Week's Changes. Recent moves in the industry include C-suite changes at Ovid Therapeutics and Genor Biopharma, plus Structure Therapeutics acquires chief development...... ow.ly/wEei105JcBf #PharmaScrip

ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class ? The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new...      Related StoriesExecutives On The Move: Four New CEOs... ow.ly/oBkm105Jf35 #PharmaScrip

Vanda’s Tradipitant Gets CRL In Gastroparesis But Another NDA Filing Is Still On. The company will file a new drug application with the US FDA by the end of the year for tradipitant...      Related StoriesVanda’s Tradipitant Gets CRL In... ow.ly/1PkR105Jgfm #PharmaScrip

Roche’s Xofluza Can Reduce Flu Transmission, Giving It Potential Market Boost. The company said the CENTERSTONE study marked the first time a global Phase III trial showed reduced transmission of influenza.      Related StoriesTaisho Makes... ow.ly/P7Fz105Jgfn #PharmaScrip

Aligos’s MASH Data Look Competitive, But Path Forward Is Unclear. Aligos’s THRβ agonist yielded hepatic fat reduction equal to or better than its class, but the biotech prefers moving forward...      Related StoriesRoche’s Xofluza Can... ow.ly/2XK1105Jhqa #PharmaScrip

Chinese Firms To Dominate Domestic Cell Therapy Market As Gilead Exits. Gilead’s divestment from a 50-50 joint venture with local partner, which came to light recently, will leave China’s cell therapies...      Related StoriesAligos’s MASH... ow.ly/JAxl105Jjv0 #PharmaScrip

Novo Nordisk’s Monlunabant Expectations Dashed By Phase II Data. Mid-stage clinical data show why cannabinoid receptor inverse agonism is an unfavored approach to obesity treatment.      Related StoriesEdgewise’s Early Cardiomyopathy... ow.ly/laG8105JluW #PharmaScrip

Edgewise’s Early Cardiomyopathy Data Builds Case For A Blockbuster. The EDG-7500 results have seen the company’s share price rocket, thanks to a potential advantage over existing treatments for the...      Related StoriesNovo Nordisk’s... ow.ly/vTrP105Jlv1 #PharmaScrip

Sanofi’s HERCULES Data In MS May Offer Path To Approval For Tolebrutinib. Delaying disease progression in non-relapsing secondary multiple sclerosis may get the BTK inhibitor approved, despite previous pivotal trial failures in...... ow.ly/gmY1105JnYt #PharmaScrip

Sanofi’s Sarclisa Steals A March On Darzalex In Myeloma With FDA First-Line Nod. The Paris-headquartered major's anti-CD38 antibody has long lived in the shadow of Johnson & Johnson and Genmab’s Darzalex but the...      Related StoriesDeal... ow.ly/gmYi105JnYu #PharmaScrip

Deal Watch: A Closer Look At Boehringer Ingelheim’s Partnering Strategy. Plus deals involving AbbVie/Ripple, Novo Nordisk/Korro Bio, Novo Nordisk/NanoVation, Bharat, Alopexx, Gilead/Genesis, Lilly/Genetic Leap, Contraline/Population... ow.ly/LgRb105JnYv #PharmaScrip

BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps? Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the...        ow.ly/KCvb105Jzfj #PharmaScrip

Building On 100 Years In India: The Next Big Things On GSK’s Horizon. GSK’s India chief talks to Scrip about new category creation in adult immunization with Shingrix seeing strong uptake, Nucala and...      Related StoriesESMO 24: Bayer... ow.ly/whRH105JzQS #PharmaScrip

Pipeline Watch: Fourteen Approvals And Forty-Four Phase III Readouts. Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...      Related... ow.ly/u5zT105JB31 #PharmaScrip

Trio Of US Approvals Pushes UCB's Bimzelx Towards Blockbuster Status. The Belgian drugmaker’s dual IL-17A and IL-17F inhibitor is now approved for four indications in the US, with another in...      Related StoriesBreast Follows Lung In... ow.ly/uzYL105JB32 #PharmaScrip